About Capricor Therapeutics, Inc. - Common Stock (CAPR)
Capricor Therapeutics is a clinical-stage biotechnology company focused on developing innovative cellular therapeutics to treat rare and chronic diseases. The company primarily works on harnessing the potential of stem cell-derived therapies, with a particular emphasis on cardiac and musculoskeletal conditions. Capricor aims to advance its proprietary technologies through rigorous research and development, striving to bring transformative treatment options to patients with unmet medical needs. By leveraging its expertise and pioneering spirit, Capricor seeks to make significant contributions to the field of regenerative medicine. Read More
Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR) of a class action securities lawsuit.
Capricor (NASDAQ: CAPR) shares collapsed 60% to 70% on July 27, 2026 after FDA staff briefing documents raised significant concerns regarding the evidence supporting Deramiocel's efficacy ahead of the July 29, 2026 advisory committee meeting. CAPR shareholders who saw their investment drop after the FDA briefing documents are encouraged to act promptly. To respond while the investigation is active, submit your CAPR loss information or contact Levi & Korsinsky, LLP at (212) 363-7500.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor investors have until September 28, 2026 to file a lead plaintiff motion.
The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Glancy Prongay Wolke & Rotter LLP (“GPWR”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (“Capricor” or the “Company”) for potential violations of the federal securities laws.
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop.
Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors concerning the Company’s possible violations of federal securities laws.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the investing public.
The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Capricor Therapeutics (NASDAQ:CAPR) executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.
Speaking at a Goldman Sac
